Triple Negative Breast Neoplasms
62
14
21
15
Key Insights
Highlights
Success Rate
52% trial completion
Published Results
16 trials with published results (26%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
22.6%
14 terminated out of 62 trials
51.7%
-34.9% vs benchmark
13%
8 trials in Phase 3/4
107%
16 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 15 completed trials
Clinical Trials (62)
Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Sacituzumab Govitecan and Q901 in Advanced TNBC
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers